Jianyu Weng

8PUBLICATIONS
19CO-AUTHORS
Regenerative medicine (incl. stem cells)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMedical mycologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 31, 2026
Integrated Transcriptomic Analysis and Molecular Modeling Identify ENO1 and Naftopidil as Candidates for Chronic Myelomonocytic Leukemia.

|Dec 09, 2025
Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial.

Honghong Yan, Xin Huang, Ping Wu

|Dec 22, 2023
Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience.

Chao Li, ChengXin Deng, Ping Wu

|Apr 25, 2023
Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-β-SMAD2/3 pathway.

Ruohao Xu, Miao Wu, Yawen Wang

|Mar 29, 2021
C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study.

Jinghua Wang, Weida Wang, Hao Chen

|Feb 25, 2020
von Willebrand Factor as a Predictor for Transplant-Associated Thrombotic Microangiopathy.

Zhenzhen Xu, Chengwei Luo, Peilong Lai

Pageof 2

Frequent Collaborators

2 joint publications

Lingji Zeng

2 joint publications

Suxia Geng

2 joint publications

Xin Du

1 joint publications

Qian Wang